Trial Outcomes & Findings for An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants (NCT NCT02761187)

NCT ID: NCT02761187

Last Updated: 2025-02-24

Results Overview

Charlson Comorbidity Index (CCI) was used to represent number of participants with co-morbidities. CCI is a method of categorizing comorbidities of participants. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a participant. A score of 0 = no comorbidities found, 1 = not ill, 2 = mildly ill, 3 = moderately ill, 4 = severely ill, and ≥5 = moribund. The higher the score, the more likely the predicted outcome resulted in mortality or higher resource use.

• Recruitment status: TERMINATED
• Target enrollment: 4253 participants
• Primary outcome timeframe: Baseline up to 5 years
• Results posted on: 2025-02-24

Participant Flow

Participants took part in the study at 130 investigative sites in China, Taiwan, Belgium, France, Germany, Greece, Israel, Italy, Spain, Turkey, United Kingdom, Brazil, Colombia, Mexico, United States from 1 July 2016 to 30 September 2021. A total of 4253 participants were enrolled in this study.

Prospective data was collected for newly diagnosed multiple myeloma (NDMM) and Relapsed/Refractory multiple myeloma (RRMM) participants. Participants were also divided for analysis of some part of this study according to lines of therapy (LOT) they received. The final outcomes analysis performed at the end of study included 3263 participants excluding 990 participants from 4253 due to concerns around the robustness of data. Participants who received >1 LOT were counted more than once.

Participant milestones

Measure	Newly Diagnosed (ND) MM Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	Relapsed/Refractory (R/R) MM Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).
Overall Study STARTED	2338	1915
Overall Study 1st Line of Therapy	2193	68
Overall Study 2nd Line of Therapy	928	950
Overall Study 3rd Line of Therapy	406	1049
Overall Study 4th Line of Therapy	185	727
Overall Study >4th Line of Therapy	153	767
Overall Study Line of Therapy: Unknown	54	93
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	2338	1915

Reasons for withdrawal

Measure	Newly Diagnosed (ND) MM Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	Relapsed/Refractory (R/R) MM Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).
Overall Study Too ill to Participate	13	8
Overall Study Patient declined participation and declined follow-up for survival	34	26
Overall Study Patient withdrew consent	64	58
Overall Study Physician discretion	4	8
Overall Study Change in physician or transferred to another treatment center	72	62
Overall Study On Hospice	20	26
Overall Study Deceased	474	642
Overall Study Lost to Follow-up	73	63
Overall Study Due to study discontinued at site	100	85
Overall Study Reason not Specified	1484	937

Baseline Characteristics

Number analyzed are the number of participants available for baseline age continuous.

Baseline characteristics by cohort

Measure	NDMM n=2338 Participants Participants with newly diagnosed MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	RRMM n=1915 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	Total n=4253 Participants Total of all reporting groups
Age, Continuous	64.7 years STANDARD_DEVIATION 10.94 • n=2337 Participants • Number analyzed are the number of participants available for baseline age continuous.	66.0 years STANDARD_DEVIATION 10.42 • n=1914 Participants • Number analyzed are the number of participants available for baseline age continuous.	65.2 years STANDARD_DEVIATION 10.72 • n=4251 Participants • Number analyzed are the number of participants available for baseline age continuous.
Sex: Female, Male Female	1317 Participants n=2338 Participants	1128 Participants n=1915 Participants	2445 Participants n=4253 Participants
Sex: Female, Male Male	1021 Participants n=2338 Participants	787 Participants n=1915 Participants	1808 Participants n=4253 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	348 Participants n=2338 Participants	285 Participants n=1915 Participants	633 Participants n=4253 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	1297 Participants n=2338 Participants	1004 Participants n=1915 Participants	2301 Participants n=4253 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	693 Participants n=2338 Participants	626 Participants n=1915 Participants	1319 Participants n=4253 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=2338 Participants	0 Participants n=1915 Participants	0 Participants n=4253 Participants
Race (NIH/OMB) Asian	230 Participants n=2338 Participants	160 Participants n=1915 Participants	390 Participants n=4253 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=2338 Participants	0 Participants n=1915 Participants	0 Participants n=4253 Participants
Race (NIH/OMB) Black or African American	153 Participants n=2338 Participants	111 Participants n=1915 Participants	264 Participants n=4253 Participants
Race (NIH/OMB) White	1506 Participants n=2338 Participants	1273 Participants n=1915 Participants	2779 Participants n=4253 Participants
Race (NIH/OMB) More than one race	25 Participants n=2338 Participants	16 Participants n=1915 Participants	41 Participants n=4253 Participants
Race (NIH/OMB) Unknown or Not Reported	424 Participants n=2338 Participants	355 Participants n=1915 Participants	779 Participants n=4253 Participants

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: All Enrolled Population included all participants who signed the inform consent form. Overall number of participants analyzed is the number of participants available for analysis.

Charlson Comorbidity Index (CCI) was used to represent number of participants with co-morbidities. CCI is a method of categorizing comorbidities of participants. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a participant. A score of 0 = no comorbidities found, 1 = not ill, 2 = mildly ill, 3 = moderately ill, 4 = severely ill, and ≥5 = moribund. The higher the score, the more likely the predicted outcome resulted in mortality or higher resource use.

Outcome measures

Measure	RRMM n=1440 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=1761 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Participants With Co-morbidities >5	19 Participants	38 Participants	—	—	—	—
Number of Participants With Co-morbidities 4-5	60 Participants	66 Participants	—	—	—	—
Number of Participants With Co-morbidities Missing	50 Participants	71 Participants	—	—	—	—
Number of Participants With Co-morbidities 0-1	1064 Participants	1279 Participants	—	—	—	—
Number of Participants With Co-morbidities 2-3	247 Participants	307 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Baseline

Population: All Enrolled Population included all participants who signed the inform consent form.

Participants diagnosed with NDMM and R/RMM were determined at the start of the study.

Outcome measures

Measure	RRMM n=1915 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=2338 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Participants Diagnosed With Newly Diagnosed Multiple Myeloma (NDMM) and Relapsed/Refractory Multiple Myeloma (R/RMM)	1915 Participants	2338 Participants	—	—	—	—

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: At Baseline

Population: All Enrolled Population included all participants who signed informed consent. Overall number of participants analyzed is the number of participants available for analysis.

ECOG-PS measured on-therapy (time between first dose and last dose date with a 30-day lag) assessed participant's performance status on 6 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (>50% of waking hours), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair >50% of waking hours; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead. The line of Therapy was determined at study entry.

Outcome measures

Measure	RRMM n=1440 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=1761 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Participants With ECOG (Eastern Cooperative Oncology Group) Performance Status Grade 0	710 Participants	714 Participants	—	—	—	—
Number of Participants With ECOG (Eastern Cooperative Oncology Group) Performance Status Grade 1	559 Participants	727 Participants	—	—	—	—
Number of Participants With ECOG (Eastern Cooperative Oncology Group) Performance Status Grade 2	113 Participants	171 Participants	—	—	—	—
Number of Participants With ECOG (Eastern Cooperative Oncology Group) Performance Status Grade 3	22 Participants	61 Participants	—	—	—	—
Number of Participants With ECOG (Eastern Cooperative Oncology Group) Performance Status Grade 4	2 Participants	13 Participants	—	—	—	—
Number of Participants With ECOG (Eastern Cooperative Oncology Group) Performance Status Missing	34 Participants	75 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At Baseline

Population: All Enrolled Population included all participants who signed the inform consent form. Overall number of participants analyzed is the number of participants available for analysis.

Frailty is defined as the combination of unintentional weight loss, exhaustion, low physical activity, slow walking speed, and muscular weakness. The Myeloma Frailty Index is a composite index that was calculated using the points system, which produces a range of values from 0 to 5. Participants with score 0= fit, score 1= intermediate, and score ≥2= frail. Higher score indicates likeliness that the predicted outcome will result in frailty. The line of Therapy was determined at study entry.

Outcome measures

Measure	RRMM n=1440 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=1761 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Participants With Myeloma Frailty Index 0: Fit	428 Participants	517 Participants	—	—	—	—
Number of Participants With Myeloma Frailty Index 1: Intermediate	202 Participants	218 Participants	—	—	—	—
Number of Participants With Myeloma Frailty Index ≥2: Frail	130 Participants	190 Participants	—	—	—	—
Number of Participants With Myeloma Frailty Index Missing	680 Participants	836 Participants	—	—	—	—

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: At Baseline

Population: All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis.

FISH methodology was reported with Yes/No results for the following tests: deletion (17p)/p53 [Del(17p)/p53], translocation (4,14) [t(4,14)], and translocation (14,16) [t(14,16)].

Outcome measures

Measure	RRMM n=686 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=1790 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy n=458 Participants The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=249 Participants The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy n=80 Participants The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(4,14) · Not Done - Inferred	18 Participants	401 Participants	2 Participants	2 Participants	0 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(4,14) · Missing	480 Participants	108 Participants	382 Participants	213 Participants	68 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(14,16) · No	157 Participants	1007 Participants	67 Participants	27 Participants	12 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(14,16) · Not Reported/Performed	20 Participants	208 Participants	7 Participants	4 Participants	0 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(14,16) · Yes	7 Participants	50 Participants	0 Participants	3 Participants	0 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(14,16) · Not Done - Inferred	18 Participants	416 Participants	2 Participants	2 Participants	0 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(14,16) · Missing	484 Participants	109 Participants	382 Participants	213 Participants	68 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(4,14) · Yes	24 Participants	116 Participants	4 Participants	5 Participants	3 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(4,14) · No	144 Participants	957 Participants	63 Participants	25 Participants	9 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) Del(17p)/p53 · Missing	479 Participants	107 Participants	382 Participants	214 Participants	68 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) t(4,14) · Not Reported/Performed	20 Participants	208 Participants	7 Participants	4 Participants	0 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) Del(17p)/p53 · Not Reported/Performed	20 Participants	208 Participants	7 Participants	4 Participants	0 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) Del(17p)/p53 · Yes	23 Participants	126 Participants	12 Participants	5 Participants	0 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) Del(17p)/p53 · No	147 Participants	950 Participants	55 Participants	24 Participants	12 Participants	—
Number of Participants Evaluated for Cytogenetics Using Fluorescence in Situ Hybridization (FISH) Del(17p)/p53 · Not Done - Inferred	17 Participants	399 Participants	2 Participants	2 Participants	0 Participants	—

PRIMARY outcome

Timeframe: At Baseline

Population: All Enrolled Population included all participants who signed informed consent. Overall number of participants are the number of participants available for analysis.

ISS disease stages were defined as I:low risk, β2-Microglobulin<3.5mg/L, albumin≥3.5g/dL, II:not stage I or III, III:high risk,β2-Microglobulin≥5.5mg/L). R-ISS is based on ISS, chromosomal abnormalities (CA), and lactate dehydrogenase (LDH). R-ISS disease stages were defined as I: ISS Stage I and standard risk CA by FISH and normal LDH (i.e. <=300 U/L), II: Neither R-ISS Stage I nor Stage III, III: ISS Stage III and either high risk CA by FISH or high LDH (i.e. >300 U/L).

Outcome measures

Measure	RRMM n=1440 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=1761 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage R-ISS Missing	946 Participants	1170 Participants	—	—	—	—
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage ISS Stage I	236 Participants	395 Participants	—	—	—	—
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage ISS Stage II	267 Participants	387 Participants	—	—	—	—
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage ISS Stage III	297 Participants	520 Participants	—	—	—	—
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage ISS Not Available	376 Participants	138 Participants	—	—	—	—
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage ISS Missing	264 Participants	321 Participants	—	—	—	—
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage R-ISS Stage I	40 Participants	127 Participants	—	—	—	—
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage R-ISS Stage II	145 Participants	319 Participants	—	—	—	—
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage R-ISS Stage III	24 Participants	76 Participants	—	—	—	—
Number of Participants Evaluated for International Staging System (ISS)/ Revised (R)-ISS Stage R-ISS Not available	285 Participants	69 Participants	—	—	—	—

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. Overall number analyzed are the number of participants with data available for analyses. The data is reported as per the known line of therapies.

Data was analyzed for participants with and without stem cell transplant for all enrolled population, included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data.

Outcome measures

Measure	RRMM n=575 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=1597 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy n=390 Participants The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=227 Participants The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy n=77 Participants The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Duration of Treatment for Participants With and Without Stem Cell Transplant	6.4 months Interval 0.0 to 57.0	4.5 months Interval 0.0 to 45.0	9.2 months Interval 0.0 to 80.0	11.5 months Interval 0.0 to 68.0	11.5 months Interval 0.0 to 52.0	—

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: All Enrolled Population, included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis.

Overall Survival was defined as the number of months from the index regimen start date within each line of therapy, starting with the line during study entry, until the date of death. The Kaplan Meier estimates was used for the analysis.

Outcome measures

Measure	RRMM n=1331 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=1790 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy n=1050 Participants The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=739 Participants The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy n=453 Participants The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Overall Survival (OS)	47.67 months Interval 45.34 to The upper limit of CI was not estimable due to an insufficient number of participants with events of death.	NA months Median and 95% confidence interval (CI) was not estimable due to an insufficient number of participants with events of death.	32.07 months Interval 26.84 to 39.56	20.60 months Interval 17.51 to 23.36	13.44 months Interval 10.91 to 15.9	—

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Disease progression status was assessed by physician interpretation of IMWG Response criteria.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis.

The line of Therapy was determined at study entry. The Kaplan Meier estimates was used for the analysis.

Outcome measures

Measure	RRMM n=1331 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=1790 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy n=1050 Participants The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=739 Participants The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy n=453 Participants The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Time to Next Therapy	15.44 months Interval 13.63 to 17.08	30.39 months Interval 26.87 to 33.74	9.46 months Interval 8.34 to 10.81	6.90 months Interval 6.11 to 7.82	5.95 months Interval 5.16 to 6.7	—

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: All Enrolled Population included all participants who signed the inform consent form, out of which 990 participants were excluded during the final analysis due to concerns around robustness of data. The data is reported as per the known line of therapies. Overall number of participants analyzed is the number of participants available for analysis.

Outcome measures

Measure	RRMM n=686 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=1790 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy n=458 Participants The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=249 Participants The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy n=80 Participants The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Participants With Stem Cell Transplant	686 Participants	1790 Participants	458 Participants	249 Participants	80 Participants	—

PRIMARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

The Global Health Status scale/QoL scale included 2 questions measured with a 7-point numeric rating scale (very poor to excellent). Raw scores are converted into scale scores ranging from 0 to 100. A higher score represents better HRQoL.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: All Enrolled Population included all participants who signed the inform consent form. Participants were reported more than once in each line of therapy. Data is reported only for 1st, 2nd 3rd and 4th line of therapy. The overall number of participants analyzed is the number of participants available for analyses.

Outcome measures

Measure	RRMM n=1685 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=2195 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy n=1279 Participants The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=845 Participants The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Participants Receiving Different Treatment Combinations Bortezomib and Melphalan (VM)	16 Participants	75 Participants	8 Participants	3 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Lenalidomide (R)	39 Participants	21 Participants	22 Participants	5 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Daratumumab-Bortezomib (dara-V)	110 Participants	7 Participants	78 Participants	46 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Pomalidomide and Dexamethasone (PomD)	12 Participants	0 Participants	66 Participants	39 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Daratumumab (Dara)	15 Participants	0 Participants	21 Participants	56 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Bortezomib and Lenalidomide (VR)	86 Participants	560 Participants	19 Participants	10 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Bortezomib and Cyclophosphamide (VC)	99 Participants	497 Participants	43 Participants	18 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Bortezomib and Thalidomide (VT)	60 Participants	272 Participants	10 Participants	11 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Lenalidomide and Dexamethasone (RD)	218 Participants	86 Participants	126 Participants	30 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Cyclophosphamide and Thalidomide (CT)	37 Participants	60 Participants	11 Participants	5 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Melphalan and Thalidomide (MT)	3 Participants	10 Participants	4 Participants	3 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Thalidomide and Dexamethasone (TD)	1 Participants	7 Participants	5 Participants	2 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Bortezomib and dexamethasone (VD)	47 Participants	95 Participants	18 Participants	6 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Ixazomib and Lenalidomide (IR)	96 Participants	4 Participants	115 Participants	34 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Carfilzomib and Lenalidomide (KR)	112 Participants	63 Participants	42 Participants	18 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Bortezomib and Pomalidomide (VPom)	7 Participants	0 Participants	2 Participants	6 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Carfilzomib and Pomalidomide (KPom)	27 Participants	1 Participants	22 Participants	12 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Carfilzomib and dexamethasone (KD)	59 Participants	3 Participants	76 Participants	46 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Daratumumab-Ixazomib (dara-I)	12 Participants	1 Participants	7 Participants	3 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Daratumumab-Lenalidomide (dara-R)	149 Participants	3 Participants	70 Participants	31 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Daratumumab-Pomalidomide (dara-Pom)	49 Participants	0 Participants	72 Participants	43 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Ixazomib and Dexamethasone (ID)	14 Participants	1 Participants	13 Participants	9 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Ixazomib (I)	6 Participants	0 Participants	5 Participants	4 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Elotuzumab and Lenalidomide (Elo-R)	42 Participants	7 Participants	20 Participants	10 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Elotuzumab-Pomalidomide (Elo-Pom)	6 Participants	0 Participants	10 Participants	14 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Elotuzumab-Other Regimen (Elo-Other)	4 Participants	6 Participants	4 Participants	1 Participants	—	—
Number of Participants Receiving Different Treatment Combinations Other Regimen	359 Participants	416 Participants	390 Participants	380 Participants	—	—

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: All Enrolled Population included all participants who signed informed consent. Participants were reported more than once in each line of therapy. Data is reported only for 1st, 2nd and 3rd line of therapy.

Drug classes were based on the earliest regimen in each corresponding Line of Therapy. The data for this outcome measure was analyzed as per line of therapy.

Outcome measures

Measure	RRMM n=2748 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=4224 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy n=1734 Participants The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Treatment Sequencing mAB/PI based	119 Participants	156 Participants	69 Participants	—	—	—
Number of Treatment Sequencing PI/alkylator based	137 Participants	351 Participants	57 Participants	—	—	—
Number of Treatment Sequencing IMID/alkylator based	119 Participants	123 Participants	57 Participants	—	—	—
Number of Treatment Sequencing mAB based	77 Participants	41 Participants	129 Participants	—	—	—
Number of Treatment Sequencing mAB/IMID based	213 Participants	290 Participants	128 Participants	—	—	—
Number of Treatment Sequencing mAB/alkalytor based	7 Participants	2 Participants	6 Participants	—	—	—
Number of Treatment Sequencing mAB/IMID/PI based	14 Participants	36 Participants	12 Participants	—	—	—
Number of Treatment Sequencing Cytotoxic	59 Participants	74 Participants	49 Participants	—	—	—
Number of Treatment Sequencing IMID based	361 Participants	515 Participants	118 Participants	—	—	—
Number of Treatment Sequencing PI based	204 Participants	366 Participants	101 Participants	—	—	—
Number of Treatment Sequencing Alkylator based	40 Participants	79 Participants	33 Participants	—	—	—
Number of Treatment Sequencing PI/IMID based	295 Participants	608 Participants	115 Participants	—	—	—
Number of Treatment Sequencing PI/IMID/alkylator based	14 Participants	34 Participants	7 Participants	—	—	—
Number of Treatment Sequencing Other	32 Participants	59 Participants	46 Participants	—	—	—
Number of Treatment Sequencing Unknown	1057 Participants	1490 Participants	807 Participants	—	—	—

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: All Enrolled Population included all participants who signed informed consent. Participants received more than one LOT and are counted in more than one LOT. The data is reported as per the known line of therapies. Participants were counted multiple times in different categories. The overall number of participants analyzed is the number of participants available for analyses.

Outcome measures

Measure	RRMM n=1878 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=2260 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy n=1416 Participants The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=700 Participants The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy n=500 Participants The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Reasons for Treatment Modifications COVID-19 Restrictions	21 Participants	13 Participants	22 Participants	11 Participants	8 Participants	—
Reasons for Treatment Modifications Adverse Event Related to Drug	676 Participants	920 Participants	459 Participants	240 Participants	187 Participants	—
Reasons for Treatment Modifications Other	333 Participants	425 Participants	248 Participants	110 Participants	81 Participants	—
Reasons for Treatment Modifications Planned Change	274 Participants	386 Participants	205 Participants	99 Participants	62 Participants	—
Reasons for Treatment Modifications Adverse Event Not Related to MM Therapy Drug	243 Participants	234 Participants	179 Participants	91 Participants	62 Participants	—
Reasons for Treatment Modifications Current Dose Tolerated, Dose Increased	107 Participants	110 Participants	105 Participants	47 Participants	30 Participants	—
Reasons for Treatment Modifications Dose Delay Due to Toxicity	91 Participants	63 Participants	65 Participants	32 Participants	22 Participants	—
Reasons for Treatment Modifications Patient/Family Preference	58 Participants	53 Participants	39 Participants	19 Participants	16 Participants	—
Reasons for Treatment Modifications Treatment Fatigue	36 Participants	25 Participants	33 Participants	17 Participants	13 Participants	—
Reasons for Treatment Modifications Lack of Response	23 Participants	16 Participants	27 Participants	11 Participants	13 Participants	—
Reasons for Treatment Modifications Relapse - Biochemical Progression	17 Participants	9 Participants	19 Participants	11 Participants	7 Participants	—
Reasons for Treatment Modifications COVID-19 Diagnosis (Confirmed Positive)	11 Participants	5 Participants	7 Participants	8 Participants	3 Participants	—
Reasons for Treatment Modifications Relapse - Symptomatic/Clinical Progression	10 Participants	5 Participants	3 Participants	2 Participants	3 Participants	—
Reasons for Treatment Modifications COVID-19 Diagnosis (Suspected Positive)	0 Participants	3 Participants	1 Participants	0 Participants	0 Participants	—
Reasons for Treatment Modifications Missing	13 Participants	6 Participants	4 Participants	2 Participants	1 Participants	—

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: As the study was early terminated data was not collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Baseline up to 5 years

Population: Participants who received Takeda products and signed informed consent form were included in the analysis. As pre-specified in SAP, data for treatment-emergent adverse events was planned to be collected and reported for Takeda products only. Participants were counted more than once in each line of therapy towards the total. The data is reported as per the known line of therapies.

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Treatment discontinuation includes temporary and permanent discontinuation, drug modification, and second primary malignancies.

Outcome measures

Measure	RRMM n=1878 Participants Participants diagnosed with RRMM who previously received 1 to 3 prior lines of therapy were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	NDMM n=2261 Participants Participants newly diagnosed with MM within 3 months from initiation of treatment were enrolled for 3 years, and followed for at least 2 years, until death, or the end of the study, whichever comes first (up to approximately 5 years).	3rd Line of Therapy n=1455 Participants The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=912 Participants The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy n=500 Participants The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Unknown Missing line of therapy with respect to recorded regimen or have not observed any regimen with line of therapy on or after study entry. Participants were observed until study discontinuation, death or end of study (up to approximately 5 years).
Number of Participants With Atleast One Treatment-emergent Adverse Events Leading to Treatment Discontinuation	275 Participants	375 Participants	178 Participants	98 Participants	95 Participants	—

Adverse Events

1st Line of Therapy

Serious events: 269 serious events

Other events: 306 other events

Deaths: 351 deaths

2nd Line of Therapy

Serious events: 101 serious events

Other events: 125 other events

Deaths: 418 deaths

3rd Line of Therapy

Serious events: 82 serious events

Other events: 79 other events

Deaths: 420 deaths

4th Line of Therapy

Serious events: 43 serious events

Other events: 39 other events

Deaths: 348 deaths

>4th Line of Therapy

Serious events: 38 serious events

Other events: 32 other events

Deaths: 234 deaths

Robustness Concerns: 1st Line of Therapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 58 deaths

Robustness Concerns: 2nd Line of Therapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 72 deaths

Robustness Concerns: 3rd Line of Therapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 65 deaths

Robustness Concerns: 4th Line of Therapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 32 deaths

Robustness Concerns: >4th Line of Therapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 6 deaths

Robustness Concerns: Unknown Line of Therapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 28 deaths

Serious adverse events

Measure	1st Line of Therapy n=1849 participants at risk The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	2nd Line of Therapy n=773 participants at risk The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	3rd Line of Therapy n=455 participants at risk The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=239 participants at risk The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy n=181 participants at risk The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Robustness Concerns: 1st Line of Therapy The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in 1st line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: 2nd Line of Therapy The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in 2nd line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: 3rd Line of Therapy The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in 3rd line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: 4th Line of Therapy The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in 4th line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: >4th Line of Therapy The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in \>4th line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: Unknown Line of Therapy The 'Unknown Line of Therapy' indicates either: 1) participant was on a regimen on or after study entry, but missing line of therapy with respect to that regimen or 2) have not observed any regimen with line of therapy on or after study entry. Only participants in unknown line of therapy with concerns around the robustness of data were included in this arm.
Blood and lymphatic system disorders Febrile neutropenia	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Anaemia	0.32% 6/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.84% 2/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.7% 3/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Febrile bone marrow aplasia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Haematotoxicity	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Neutropenia	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Pancytopenia	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Thrombocytopenia	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.88% 4/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.7% 4/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	2.2% 4/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Acute myocardial infarction	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Angina pectoris	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Atrial fibrillation	0.38% 7/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	2.2% 4/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Atrial flutter	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Chest pain	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Bradycardia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiac arrest	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiac failure	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiac failure acute	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiac failure congestive	0.49% 9/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiac flutter	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiogenic shock	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiomyopathy	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Coronary artery disease	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Coronary artery stenosis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Coronary artery thrombosis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Microvascular coronary artery disease	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Myocardial infarction	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Pericardial effusion	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Pericarditis	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Restrictive cardiomyopathy	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Supraventricular tachycardia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Systolic dysfunction	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Endocrine disorders Parathyroid disorder	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Abdominal pain	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Abdominal pain upper	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Colitis	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Constipation	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Diarrhoea	0.43% 8/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Diverticular perforation	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Enteritis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Enterocolitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Gastric ulcer	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Intestinal perforation	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Large intestine perforation	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Nausea	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Pancreatic duct obstruction	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Small intestinal obstruction	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Stomatitis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Vomiting	0.32% 6/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Asthenia	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Death	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Disease progression	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Fatigue	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders General physical health deterioration	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.66% 3/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Generalised oedema	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Hyperthermia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Influenza like illness	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Malaise	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Multiple organ dysfunction syndrome	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Non-cardiac chest pain	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Oedema peripheral	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Pain	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Pyrexia	0.54% 10/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.88% 4/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.84% 2/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Hepatobiliary disorders Biliary obstruction	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Hepatobiliary disorders Cholecystitis acute	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Hepatobiliary disorders Cholelithiasis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Hepatobiliary disorders Gallbladder volvulus	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Hepatobiliary disorders Jaundice	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Immune system disorders Cytokine release syndrome	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Abdominal sepsis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Abscess limb	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Atypical pneumonia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Bronchitis	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Bronchopulmonary aspergillosis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Bursitis infective	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations COVID-19	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations COVID-19 pneumonia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Cellulitis	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Cellulitis of male external genital organ	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Clostridium difficile colitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Cytomegalovirus infection reactivation	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Device related infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Diarrhoea infectious	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Diverticulitis	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Ear infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Endocarditis bacterial	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Enterococcal bacteraemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Intestinal sepsis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Enterococcal sepsis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Escherichia bacteraemia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Febrile infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Gastroenteritis	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Gastroenteritis viral	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Gastrointestinal infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Groin abscess	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Herpes zoster	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Influenza	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Kidney infection	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Klebsiella infection	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Lower respiratory tract infection	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.8% 8/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Meningitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Meningoencephalitis herpetic	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Metapneumovirus infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Osteomyelitis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Parotitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pneumocystis jirovecii pneumonia	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pneumonia	2.3% 42/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	2.2% 17/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	3.7% 17/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	2.1% 5/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.7% 3/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pneumonia bacterial	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pneumonia influenzal	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pneumonia parainfluenzae viral	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pneumonia pneumococcal	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pneumonia viral	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Postoperative wound infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pyelonephritis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Respiratory tract infection	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.65% 5/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Respiratory tract infection viral	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Rhinitis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Sepsis	0.43% 8/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.52% 4/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.66% 3/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Sepsis syndrome	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Septic shock	0.32% 6/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Staphylococcal infection	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Staphylococcal sepsis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Streptococcal sepsis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Systemic candida	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Upper respiratory tract infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Loss of consciousness	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Urinary tract infection	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.3% 3/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Urosepsis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Viral upper respiratory tract infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Accidental overdose	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Ankle fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Fall	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Femoral neck fracture	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Femur fracture	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Hip fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Humerus fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Limb injury	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Lower limb fracture	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Lumbar vertebral fracture	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Osteochondral fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Pelvic fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Post procedural fever	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Postoperative respiratory distress	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Spinal compression fracture	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Thoracic vertebral fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Tibia fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Toxicity to various agents	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Blood creatinine increased	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Cardiac murmur	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Ejection fraction decreased	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Human metapneumovirus test positive	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Influenza A virus test positive	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Liver function test increased	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Platelet count decreased	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Respirovirus test positive	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Rotavirus test positive	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Rubulavirus test positive	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations SARS-CoV-2 test positive	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Troponin increased	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations White blood cell count decreased	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Dehydration	0.32% 6/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Diabetes mellitus	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Fluid retention	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.84% 2/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hyperkalaemia	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hypocalcaemia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hypoglycaemia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hypokalaemia	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hyponatraemia	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hypovolaemia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Tumour lysis syndrome	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Back pain	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Bone pain	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Chest wall haematoma	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Muscular weakness	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Myalgia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Osteolysis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Osteonecrosis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Pain in extremity	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Pathological fracture	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Spinal osteoarthritis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Spinal pain	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bone neoplasm	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bowen's disease	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Extranodal marginal zone B-cell lymphoma (MALT type)	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastrointestinal stromal tumour	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Intraductal proliferative breast lesion	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Invasive ductal breast carcinoma	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung adenocarcinoma stage III	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm malignant	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant pleural effusion	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to bone	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm progression	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Papillary thyroid cancer	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Plasma cell leukaemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Plasma cell myeloma	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.88% 4/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.7% 3/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Rectal adenoma	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cell carcinoma	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Small cell lung cancer	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Spindle cell sarcoma	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Transitional cell carcinoma	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Autonomic neuropathy	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Balance disorder	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Cerebral infarction	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Cerebrovascular accident	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.52% 4/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Dizziness	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Dysarthria	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Embolic cerebral infarction	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Embolic stroke	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Encephalopathy	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Haemorrhage intracranial	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Haemorrhagic stroke	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Headache	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Nervous system disorder	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Neuropathy peripheral	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Paraesthesia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Paralysis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Parkinson's disease	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Post stroke seizure	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Radiculopathy	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Seizure	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Somnolence	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Syncope	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Transient ischaemic attack	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Unresponsive to stimuli	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Product Issues Device loosening	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Acute psychosis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Confusional state	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Delirium	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Mental disorder	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Mental status changes	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Acute kidney injury	0.54% 10/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.88% 4/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.7% 4/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Calculus urinary	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Chronic kidney disease	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Proteinuria	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Renal failure	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Renal impairment	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Urinary incontinence	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Urinary retention	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Acute pulmonary oedema	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Acute respiratory failure	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Chronic respiratory failure	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Chylothorax	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.52% 4/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.7% 3/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Hiccups	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Lung disorder	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pulmonary hypertension	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pulmonary microemboli	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Respiratory acidosis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.32% 6/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Dermatitis allergic	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Drug eruption	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash macular	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash pruritic	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Surgical and medical procedures Toe amputation	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Deep vein thrombosis	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Embolism	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Hypotension	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Orthostatic hypotension	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Subclavian vein thrombosis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.

Other adverse events

Measure	1st Line of Therapy n=1849 participants at risk The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	2nd Line of Therapy n=773 participants at risk The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	3rd Line of Therapy n=455 participants at risk The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	4th Line of Therapy n=239 participants at risk The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	>4th Line of Therapy n=181 participants at risk The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).	Robustness Concerns: 1st Line of Therapy The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in 1st line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: 2nd Line of Therapy The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in 2nd line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: 3rd Line of Therapy The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in 3rd line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: 4th Line of Therapy The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in 4th line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: >4th Line of Therapy The most common treatment regimens prescribed in participants treated in \>4th line of therapy were mAb, PI, and IMiD+AA treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years). Only participants treated in \>4th line of therapy with concerns around the robustness of data were included in this arm.	Robustness Concerns: Unknown Line of Therapy The 'Unknown Line of Therapy' indicates either: 1) participant was on a regimen on or after study entry, but missing line of therapy with respect to that regimen or 2) have not observed any regimen with line of therapy on or after study entry. Only participants in unknown line of therapy with concerns around the robustness of data were included in this arm.
Blood and lymphatic system disorders Anaemia	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 5/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.84% 2/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.7% 3/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Anaemia of malignant disease	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Cytopenia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Haematotoxicity	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Leukocytosis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Leukopenia	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Neutropenia	0.87% 16/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.66% 3/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.3% 3/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.7% 3/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Pancytopenia	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Blood and lymphatic system disorders Thrombocytopenia	0.65% 12/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.8% 14/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	3.1% 14/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.7% 4/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	4.4% 8/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Angina pectoris	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Atrial fibrillation	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Bradycardia	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiac failure	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiac failure congestive	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Cardiomyopathy	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Diastolic dysfunction	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Palpitations	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Sinus tachycardia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Systolic dysfunction	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Tachycardia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Cardiac disorders Ventricular extrasystoles	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Congenital, familial and genetic disorders Hypertrophic cardiomyopathy	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Ear and labyrinth disorders Deafness unilateral	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Ear and labyrinth disorders Ear pain	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Ear and labyrinth disorders Tinnitus	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Ear and labyrinth disorders Vertigo	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Eye disorders Blepharitis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Eye disorders Dacryoadenitis acquired	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Eye disorders Eyelid oedema	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Eye disorders Hypermetropia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Eye disorders Myopia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Eye disorders Periorbital oedema	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Eye disorders Retinal disorder	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Eye disorders Vision blurred	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Eye disorders Visual acuity reduced	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Abdominal distension	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Abdominal pain	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Abdominal pain upper	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Aerophagia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Anal dilatation	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Anal fissure	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Colitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Constipation	0.70% 13/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.91% 7/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Diarrhoea	1.3% 24/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.8% 14/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	2.9% 13/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	2.1% 5/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Diarrhoea haemorrhagic	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Dry mouth	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Gastritis erosive	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Gastrointestinal disorder	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Haematochezia	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Haemorrhoids	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Irritable bowel syndrome	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Mouth ulceration	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Nausea	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.5% 7/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Odynophagia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Pancreatitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Stomatitis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Gastrointestinal disorders Vomiting	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Immune system disorders Hypersensitivity	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Asthenia	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.52% 4/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Chest pain	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Discomfort	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Fatigue	1.4% 25/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.3% 10/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.8% 8/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	2.1% 5/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders General physical health deterioration	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Hyperpyrexia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Influenza like illness	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Injection site pruritus	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Injection site rash	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Injection site reaction	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Malaise	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Non-cardiac chest pain	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Oedema peripheral	0.59% 11/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.52% 4/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.88% 4/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Peripheral swelling	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
General disorders Pyrexia	0.43% 8/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.66% 3/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Hepatobiliary disorders Hepatic function abnormal	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Hepatobiliary disorders Hepatomegaly	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Hepatobiliary disorders Hyperbilirubinaemia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Immune system disorders Immunosuppression	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Immune system disorders Oral allergy syndrome	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Bronchitis	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Candida sepsis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Catheter site infection	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Conjunctivitis	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Cystitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Cytomegalovirus infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Diverticulitis	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Eyelid infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Gastroenteritis	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Groin infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Herpes virus infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Herpes zoster	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Influenza	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Klebsiella infection	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Lower respiratory tract infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Lymph gland infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Oral infection	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pharyngitis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pneumonia	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.78% 6/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.66% 3/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Postoperative wound infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pseudomonal bacteraemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Pustule	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Respiratory syncytial virus infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Respiratory tract infection	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Sinusitis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Tinea versicolour	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Tongue fungal infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Tooth abscess	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Upper respiratory tract infection	0.43% 8/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.66% 3/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Urinary tract infection	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Viral infection	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Infections and infestations Viral upper respiratory tract infection	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Concussion	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Contusion	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Fall	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Femur fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Limb injury	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Rib fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Spinal compression fracture	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Toxicity to various agents	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Injury, poisoning and procedural complications Upper limb fracture	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Adenovirus test positive	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Alanine aminotransferase increased	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Aspartate aminotransferase increased	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Blood creatinine increased	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Blood glucose increased	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Gamma-glutamyltransferase increased	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Haemoglobin decreased	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Hepatic enzyme increased	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Hepatitis E virus test positive	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Lymphocyte count decreased	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Neutrophil count decreased	0.27% 5/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Platelet count decreased	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.84% 2/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Transaminases increased	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Weight decreased	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations Weight increased	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Investigations White blood cell count decreased	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.66% 3/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Decreased appetite	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Dehydration	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hyperglycaemia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hyperkalaemia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hyperlipidaemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Malnutrition	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Steroid diabetes	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Metabolism and nutrition disorders Vitamin B12 deficiency	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Arthralgia	0.32% 6/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Back pain	0.49% 9/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Bone pain	0.32% 6/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.84% 2/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Coccydynia	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Joint swelling	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Muscle spasms	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Muscular weakness	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Myalgia	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Myopathy	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Leiomyosarcoma	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Autonomic neuropathy	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Balance disorder	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Burning sensation	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Depressed level of consciousness	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Dizziness	0.43% 8/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Dysaesthesia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Dysarthria	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Formication	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Headache	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Hypoaesthesia	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Lumbosacral radiculopathy	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Neuralgia	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Neuropathy peripheral	3.5% 64/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	4.0% 31/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	3.3% 15/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	2.5% 6/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	3.9% 7/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Neurotoxicity	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Paraesthesia	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.84% 2/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Peripheral sensorimotor neuropathy	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Peripheral sensory neuropathy	2.3% 43/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.2% 9/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.66% 3/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.3% 3/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Polyneuropathy	0.32% 6/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Somnolence	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Syncope	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Nervous system disorders Tremor	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Affect lability	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Agitation	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Anxiety	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Depression	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Insomnia	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.39% 3/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.84% 2/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Mental status changes	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Mood altered	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Mood swings	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Psychiatric disorders Nervousness	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Acute kidney injury	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Cystitis noninfective	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Renal failure	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Renal impairment	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.84% 2/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Renal and urinary disorders Urethral obstruction	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Reproductive system and breast disorders Pelvic pain	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Reproductive system and breast disorders Penile erythema	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Reproductive system and breast disorders Testicular pain	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Cough	0.32% 6/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Productive cough	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Respiratory disorder	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Respiratory, thoracic and mediastinal disorders Tachypnoea	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Acne	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Decubitus ulcer	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Dermatitis allergic	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Dermatitis bullous	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Dermatitis exfoliative generalised	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Drug eruption	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Ecchymosis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Erythema	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Erythema multiforme	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Night sweats	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Pruritus	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash	0.54% 10/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	1.1% 2/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash erythematous	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash macular	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.38% 7/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash maculovesicular	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash papular	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash pruritic	0.22% 4/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Rash vesicular	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Skin mass	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Skin reaction	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Skin ulcer	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Skin and subcutaneous tissue disorders Urticaria	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Circulatory collapse	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Deep vein thrombosis	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Hypertension	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Hypotension	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Orthostatic hypotension	0.16% 3/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.26% 2/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.44% 2/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.55% 1/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Thrombophlebitis	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Vasculitis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Vascular disorders Venous thrombosis limb	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Myositis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.22% 1/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Osteonecrosis	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Pain in extremity	0.54% 10/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.13% 1/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.42% 1/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Pain in jaw	0.11% 2/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.
Musculoskeletal and connective tissue disorders Spinal pain	0.05% 1/1849 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/773 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/455 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/239 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	0.00% 0/181 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.	— 0/0 • From start of study, until death, or the end of the study, whichever comes first (up to 5 years) As per planned analysis,mortality was collected for all participants; serious/other adverse events were collected only for participants who signed an informed consent form and had robust data. Data was reported per line of therapies and robustness concerns.As pre-specified in SAP,serious and other adverse events were collected and reported for Takeda products only.A participant maybe counted across multiple lines of therapy, allowing same participant to be represented in multiple index regimens.

Additional Information

Study Director

Takeda

Phone: +1-877-825-3327

Email: TrialDisclosures@takeda.com

Results disclosure agreements

• Principal investigator is a sponsor employee In general, Investigators may publish clinical data after the earlier of (i) publication by the Sponsor or (ii) 12 months following the abandonment, early termination or database lock; provided a copy of the publication provided to Sponsor at least 30 days ahead of publication, the Sponsor's confidential information is removed as may be requested by Sponsor and Investigator defers publication for up to 60 days in the event Sponsor provides notice that it intends to file a patent application.
• Publication restrictions are in place

Restriction type: OTHER